Unique ID issued by UMIN | UMIN000026228 |
---|---|
Receipt number | R000030126 |
Scientific Title | One-year Efficacy of Adjunctive Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients with Glaucoma Inadequately Controlled under Maximum Medical Therapy |
Date of disclosure of the study information | 2017/02/20 |
Last modified on | 2017/02/20 16:55:49 |
One-year Efficacy of Adjunctive Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients with Glaucoma Inadequately Controlled under Maximum Medical Therapy
One-year efficacy of Ripasudil
One-year Efficacy of Adjunctive Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients with Glaucoma Inadequately Controlled under Maximum Medical Therapy
One-year efficacy of Ripasudil
Japan |
Prymary open angle glaucoma
Ophthalmology |
Others
NO
To evaluate the one-year efficacy, ability to lower intraocular pressure, and tolerability of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.
Safety,Efficacy
Intraocular pressure lowering effect at 12 months after treatment
Observational
20 | years-old | <= |
100 | years-old | >= |
Male and Female
Japanese men or women with primary open angle glaucoma,20 years of age or older, inadequately controlled IOP despite treatment with 3 or 4 drugs, IOP of less than 35 mmHg, and IOP difference less than 2 mm Hg between any 2 eligibility visits. We fixedthe target IOP at 18 mm Hg in the early phase, 15 mmHg in the intermidiate phase, and 12mm Hg in the late phase, according to Anderson's classification. We defined inadequately controlled IOP as a failure to decrease the IOP to its target value under the existing medical therapy.
The exclusion criteria were as follows: presence of secondary, steroid-related, or traumatic glaucoma, and narrow angles that are defined as grade 2 or less according to the Shaffer classification, as assessed using gonioscopy. We also excluded patients who had undergone ocular surgeries, including cataract surgery within the previous year; retinal laser treatment, selective laser trabeculoplasty, glaucoma surgery, or Nd:YAG laser posterior capsulotomy within the previous 90 days; and eyelid surgery within the previous 120 days. Patients with a corrected visual acuity worse than 20/200 in either eye or with severe visual field defects were also excluded.
50
1st name | |
Middle name | |
Last name | Hiroshi Inazaki |
Department of Ophthalmology and Micro-technology, Yokohama City University School of Medicine, Yokohama, Japan
Ophthalmology
4-57 Urafune, Minami,Yokohama,Kanagawa,Japan
045-261-5656
ojionobao@yahoo.co.jp
1st name | |
Middle name | |
Last name | Hiroshi Inazaki |
Department of Ophthalmology and Micro-technology, Yokohama City University School of Medicine, Yokoh
Ophthalmology
4-57 Urafune, Minami,Yokohama,Kanagawa,Japan
045-261-5656
ojionobao@yahoo.co.jp
Department of Ophthalmology and Micro-technology, Yokohama City University School of Medicine, Yokohama, Japan
Department of Ophthalmology and Micro-technology, Yokohama City University School of Medicine, Yokohama, Japan
Self funding
NO
2017 | Year | 02 | Month | 20 | Day |
Partially published
No longer recruiting
2014 | Year | 12 | Month | 01 | Day |
2014 | Year | 12 | Month | 01 | Day |
We took the observation of IOP lowering effect and adverse events.
2017 | Year | 02 | Month | 20 | Day |
2017 | Year | 02 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030126
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |